LATEST NEWS: 26 March 2026

We are delighted to announce the appointment of a new President-Elect as well as two new Elected Directors to the TROG Cancer Research Board, as ratified at our Annual General Meeting (AGM) last week.

A/Prof Hien Le, the current chair of the TROG Scientific Committee (TSC), was appointed unopposed as President-Elect. He will take on the role of President in March 2027, when A/Prof Puma Sundaresan completes her three-year term as President.

Hien is a consultant radiation oncologist and Head of Research at the Royal Adelaide Hospital and also provides patient care at Icon Cancer Centre sites in Adelaide, South Australia.

He will bring a wealth of expertise to the role of President, including a special interest in leveraging advanced technologies within both clinical practice and research.

A/Prof Nick Hardcastle and Dr Gerry Adams were appointed as Elected Directors, further expanding the Board’s breadth of expertise.

Nick (right) is Radiation Oncology Medical Physicist and Physical Sciences Research Lead at Peter MacCallum Cancer Centre , Melbourne, and a recognised leader in radiation oncology physics and clinical trial innovation.

He has served as chair of the TROG New Techniques and Technologies Committee (NTTC) and has helped position TROG at the forefront of high-quality clinical research through his governance contributions, technical expertise and collaborative leadership.

Gerry (right) is an experienced radiation oncologist practising at GenesisCare in Bundaberg, Queensland, and respected professional leader who brings valuable clinical, governance and policy expertise to the TROG Board.

He has made a significant contribution to regional radiation oncology, including serving as Dean of the Faculty of Radiation Oncology at RANZCR. With a strong commitment to equity and improved access to high-quality cancer care, he currently chairs RANZCR’s Māori, Aboriginal and Torres Strait Islander Empowerment Committee (MATEC).

Prof Annette Haworth stepped down as Board Director at the AGM, having served on the TROG Board since 2019, and been involved in our activities for more than 20 years. Annette plans to remain involved in TROG activities going forward, including the NTTC and as medical physicist for several TROG trials.

We want to say a heartfelt thank you to Annette (pictured right with Puma Sundaresan), whose contributions include as a member of the NTTC, the TSC and the TROG Radiation Therapy Quality Assurance (RTQA) team.

Annette, who was awarded Outstanding Contribution to TROG in 2007 and inducted as a Lifetime TROG Member in 2017, has represented TROG on the Global Harmonisation Group, as well as being a member of multiple Trial Management Committees.

“Annette’s contribution as an Elected Director has been as a trusted advisor, an advocate of the TROG mission and her active contributions have made a transformative impact on the Board, and strengthened our shared purpose,” A/Prof Puma Sundaresan told Members at the AGM.

Members at the AGM also voted to induct Prof Trevor Leong (left) as a Lifetime Member of TROG, recognising his extensive and valuable contributions to the organisation, including as former TROG President, TROG Scientific Committee Chair, and long-serving Board Director.

Trevor’s impactful research includes leading the landmark AGITG AG0407GR/TROG 08.08 TOPGEAR trial, which has changed practice in preoperative chemoradiotherapy for gastric cancer.

We’d also like to congratulate TROG Head of Operations – Research and Quality Assurance Alisha Moore (pictured right with Susan Goode), on reaching the impressive milestone of 20 years’ service to TROG Cancer Research in March 2026. Alisha continues to oversee coordination and integration between RTQA and Research Services departments, playing a pivotal role in developing our trial pipeline and expanding our trial activities.

• Read about the TROG 2026 ASM

• See recipients of the TROG Research Excellence Awards